OTC: LMMY
Exousia Bio, Inc.CIK 0001939937 · SIC 8200 · Educational Services
Effective December 6, 2024, there occurred a change in control of the Company. On such date, pursuant to two separate stock purchase agreements (the “Change-in-Control Agreements”), Zhang Shengwu acquired a total of 5,250,000 shares of the Company’s common stock (the “Acquired Shares”), 5,000,000… About this business →
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (LAC 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade LMMY commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Jun 16, 2026 (period ending Feb 28, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Consolidated Statements of Operations (Unaudited)
| Description | Q3 ended Feb 28, 2026 | Q3 ended Feb 28, 2025 |
|---|---|---|
| Revenue: | ||
| Total revenue / net sales | — | — |
| Cost of revenue / cost of sales | 62,108 | — |
| Gross profit | (62,108) | — |
| Operating expenses: | ||
| Demand creation / marketing | — | — |
| Operating overhead | — | 6,981 |
| Total operating expenses | 174,897 | 6,981 |
| Operating income | (237,005) | 6,981 |
| Other income/(expense), net | 217,922 | 87,110 |
| Income before income taxes | (19,083) | 80,129 |
| Income tax expense/(benefit) | — | — |
| Net income | (19,083) | 80,129 |
| Basic earnings per share | — | 0.01 |
| Diluted earnings per share | — | 0.01 |
Balance Sheets
| Description | February 28, 2026 (Unaudited) | May 31, 2025 (Audited) |
|---|---|---|
| ASSETS | ||
| Current Assets | ||
| Cash & cash equivalents | – | – |
| Accounts receivable | – | – |
| Interest receivable | – | – |
| Total current assets | – | – |
| Non-current assets | ||
| Intangibles (net) | – | – |
| Equipment (net) | 670 | – |
| Other Assets (Exousia AI) | 22,050,000 | – |
| Total Non-current Assets | 22,050,670 | – |
| TOTAL ASSETS | 22,050,670 | – |
| LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT) | ||
| Current Liabilities | ||
| Due to related party | 8,831 | – |
| Advances from related parties | 38,850 | – |
| Accounts Payable | 212,302 | – |
| Other Current Liabilities | 1,040 | – |
| Total current liabilities | 261,023 | – |
| Non-Current Liabilities | ||
| Loans from related parties | – | – |
| Note payable related party | – | – |
| Note payable others | – | – |
| Accrued Interest | – | – |
| Total non-current liabilities | – | – |
| Total Liabilities | 261,023 | – |
| Stockholders’ Equity (Deficit) | ||
| Common stock, $0.0001 par value, 100,000,000 shares authorized; 70,000,000 & 7,777,000 shares issued and outstanding as of February 2026, and May 31, 2025, respectively | 7,350 | 778 |
| Preferred Series X | – | – |
| Additional Paid-In-Capital | 22,070,920 | 30,992 |
| Accumulated Deficit | (288,623) | (31,770) |
| Total Stockholders’ equity (deficit) | 21,789,647 | – |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | 22,050,670 | – |
Statements of Cash Flows (Unaudited)
| Description | Nine months ended February 28, 2026 | Nine months ended February 28, 2025 |
|---|---|---|
| Net income (loss) | (50,897) | 80,659 |
| Adjustment as of non-cash items: | ||
| Due to Related Party | 4,881 | – |
| Due to Shareholder | 38,850 | – |
| Loan | 1490 | – |
| Depreciation | 568 | 2,519 |
| Amortization | – | 4,833 |
| Changes in operating assets and liabilities: | ||
| Increase in accrued accounts receivable | – | (3,750) |
| Account payable and accrued expenses | 181,734 | 2,277 |
| Advances from related parties | – | – |
| Net cash provided by (used in) Operating activities | 176,626 | 86,538 |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Equipment, net | (670) | – |
| Exousia Bio | (22,050,000) | – |
| Intangibles, net | – | – |
| Net cash provided by (used in) Investing activities | (22,050,670) | – |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Additional Paid-in Capital | 21,987,777 | – |
| Proceeds from note payable others | – | – |
| Proceeds from debt forgiveness related party | – | (86,538) |
| Gain from Acquisition | (175,957) | – |
| Common Stock | 62,223 | – |
| Accrued interest | – | – |
| Net cash provided by Financing activities | 21,874,043 | (86,538) |
| Increase (decrease) in cash and equivalents | – | – |
| Cash and equivalents at beginning of the period | – | 1,028 |
| Cash and equivalents at end of the period | – | 1,028 |
| Supplemental cash flow information: | ||
| Cash paid for: | ||
| Interest | – | – |
| Taxes | – | – |
| Non-cash investing and financing activities: | ||
| Proceeds of loan from related party in exchange of asset | – | – |
| Proceeds from note payable against acquisition of intangibles | – | – |
Amounts in USD as reported; EPS as reported. Statements found on the EDGAR/iXBRL face print as filed; the rest are presentation-friendly mappings of filer XBRL tags. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗
About Exousia Bio, Inc.
Source: Item 1 (Business) from the 10-K filed October 17, 2025. Description as filed by the company with the SEC.
Item 1. Business
Recent Change in Control
Effective December 6, 2024, there
occurred a change in control of the Company. On such date, pursuant to two separate stock purchase agreements (the “Change-in-Control
Agreements”), Zhang Shengwu acquired a total of 5,250,000 shares of the Company’s common stock (the “Acquired Shares”),
5,000,000 of the Acquired Shares from Dwight Witmer and 250,000 of the Acquired Shares from Stephen Townsend. The Acquired Shares represent
approximately 67.51% of the outstanding shares of the Company’s common stock and constitute voting control of the Company.
The total consideration paid by
Mr. Shengwu for the Acquired Shares was $335,910 in cash, $318,410 to Mr. Witmer and $17,500 to Mr. Townsend.
In conjunction with the Change-in-Control
Agreements, on December 6, 2024, Dwight Witmer resigned as a Director, CEO, CFO and Secretary of the Company, Stephen Townsend resigned
as a Director and COO of the Company and Zhang Shengwu was appointed as the Sole Director, President, Chief Executive Officer and Secretary
of the Company.
Background
The
Company was incorporated in Wyoming in January of 2022.
The
Company’s Registration Statement on Form S-1 was declared effective by the Securities and Exchange Commission on February 13, 2023.
This was followed by our initial offering of shares of the Company’s common stock. The initial offering concluded in May of 2023.
Business
Strategies
We
are a startup developing a business taping the eLearning market and the gaming market by teaching financial knowledge and resource management
to children. The product is to be delivered through an educational platform and, in particular, a video game marketed as twoplus1®
which for a competitive subscription fee will provide an immersive learning experience in finance and real estate. The game will a number
of revenue-generating features deployed in the game, including a possibility to trade virtual property from which LAMY intends to generate
monetary commissions.
Read full description ↓
Our
business has not suffered any bankruptcy, receivership or similar proceeding at any time. There have not been any material reclassification,
merger, consolidation, or purchase or sale of a significant amount of assets in or out of the ordinary course of business.
The
business model of our Company is deploying new technologies and trying to use innovations to reduce costs, gain competitive advantages
to significantly affect the overcoming the inertia of developing economies. The relatively small costs for starting our business, ease
of launching and being “closer” to the client than larger companies lower the barrier to creating and penetrating into the
already narrow niche of numerous competitors in our target markets.
We
are not in need for any government approval of principal products or services we provide.
Intellectual Properties
We
have trademark protected of twoplus1® brand in the United Kingdom and are in the process
of doing the same in other key regions.
1